[February 19, 2015] |
|
Acacia Research Reports Fourth Quarter and Year End Financial Results and Announces Payment of Quarterly Dividend
Acacia Research Corporation(1) (Nasdaq: ACTG) today reported
results for the three months and year ended December 31, 2014.
Fourth Quarter 2014 Results
-
Revenues were $31,030,000, as compared to $15,065,000 in the
comparable prior year quarter.
-
GAAP net loss was $16,244,000, or $0.34 per diluted share, as compared
to a GAAP net loss of $33,333,000, or $0.69 per diluted share for the
comparable prior year quarter.
-
Non-GAAP net income was $1,576,000, or $0.03 per diluted share, as
compared to a non-GAAP net loss of $10,556,000, or $0.22 per diluted
share for the comparable prior year quarter. See below for information
regarding non-GAAP measures.
-
During the fourth quarter of 2014 we acquired control of 2 new patent
portfolios.
-
Cash and cash equivalents and investments totaled $193,024,000 as of
December 31, 2014.
Fiscal Year 2014 Results
-
Revenues were $130,876,000, as compared to revenues of $130,556,000 in
the comparable prior year.
-
GAAP net loss was $66,029,000, or $1.37 per diluted share, as compared
to a GAAP net loss of $56,434,000, or $1.18 per diluted share for the
comparable prior year.
-
Non-GAAP net income was $9,328,000, or $0.18 per diluted share, as
compared to a non-GAAP net loss of $1,424,000, or $0.04 per diluted
share for the comparable prior year. See below for information
regarding non-GAAP measures.
-
During fiscal year 2014 we acquired control of 6 new patent portfolios.
Approval of Quarterly Dividend
Acacia Research Corporation also announced today that its Board of
Directors has approved a quarterly cash dividend, payable in the amount
of $0.125 per share, which will be paid on March 30, 2015, to
shareholders of record at the close of business on March 2, 2015. Future
cash dividends are expected to be paid on a quarterly basis and will be
at the discretion of the Board of Directors.
Consolidated Financial Results - Overview
Financial results and operating activities during the periods presented
included the following:
|
|
|
|
Three Months Ended December 31,
|
|
|
|
Year Ended December 31,
|
|
|
|
|
2014
|
|
|
|
2013
|
|
|
|
|
2014
|
|
|
|
|
|
2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues (in thousands)
|
|
|
|
$
|
31,030
|
|
|
|
$
|
15,065
|
|
|
|
|
$
|
130,876
|
|
|
|
|
|
$
|
130,556
|
|
Net loss (in thousands)
|
|
|
|
$
|
(16,244
|
)
|
|
|
$
|
(33,333
|
)
|
|
|
|
$
|
(66,029
|
)
|
|
|
|
|
$
|
(56,434
|
)
|
Non-GAAP net income (loss) (in thousands)
|
|
|
|
$
|
1,576
|
|
|
|
$
|
(10,556
|
)
|
|
|
|
$
|
9,328
|
|
|
|
|
|
$
|
(1,424
|
)
|
Diluted loss per share
|
|
|
|
$
|
(0.34
|
)
|
|
|
$
|
(0.69
|
)
|
|
|
|
$
|
(1.37
|
)
|
|
|
|
|
$
|
(1.18
|
)
|
Pro forma non-GAAP net earnings (loss) per common share - diluted
|
|
|
|
$
|
0.03
|
|
|
|
$
|
(0.22
|
)
|
|
|
|
$
|
0.18
|
|
|
|
|
|
$
|
(0.04
|
)
|
New agreements executed
|
|
|
|
33
|
|
|
|
24
|
|
|
|
|
88
|
|
|
|
|
|
120
|
|
Licensing and enforcement programs generating revenues
|
|
|
|
27
|
|
|
|
23
|
|
|
|
|
46
|
|
|
|
|
|
53
|
|
Licensing and enforcement programs with initial revenues
|
|
|
|
5
|
|
|
|
4
|
|
|
|
|
15
|
|
|
|
|
|
23
|
|
New patent portfolios
|
|
|
|
2
|
|
|
|
3
|
|
|
|
|
6
|
|
|
|
|
|
25
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Summary Financial Results
For the Three Months and Fiscal Years Ended December 31, 2014 and
2013
Revenues:
|
|
|
|
Three Months Ended December 31,
|
|
|
|
|
Year Ended December 31,
|
|
|
|
|
2014
|
|
|
|
|
2013
|
|
|
|
|
|
2014
|
|
|
|
|
2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues (in thousands)
|
|
|
|
$
|
31,030
|
|
|
|
|
$
|
15,065
|
|
|
|
|
|
$
|
130,876
|
|
|
|
|
$
|
130,556
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
New agreements executed
|
|
|
|
33
|
|
|
|
|
24
|
|
|
|
|
|
88
|
|
|
|
|
120
|
Licensing and enforcement programs generating revenues
|
|
|
|
27
|
|
|
|
|
23
|
|
|
|
|
|
46
|
|
|
|
|
53
|
Licensing and enforcement programs with initial revenues
|
|
|
|
5
|
|
|
|
|
4
|
|
|
|
|
|
15
|
|
|
|
|
23
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fourth Quarter 2014 compared to Fourth Quarter 2013. Revenues in
the fourth quarter of 2014 increased $15,965,000, or 106%, to
$31,030,000, as compared to $15,065,000 in the comparable prior year
quarter. In the fourth quarter of 2014, three licensees
individually accounted for 35%, 19% and 10% of revenues recognized, as
compared to two licensees individually accounting for 35%
and 11% of revenues recognized during the fourth quarter of 2013.
Fiscal Year 2014 compared to Fiscal Year 2013. Fiscal year 2014
revenues were $130,876,000, relatively consistent with fiscal year 2013
revenues of $130,556,000. In fiscal year 2014, two licensees
each individually accounted for 22% of revenues recognized, as compared
to two licensees individually accounting for 38% and 16% of
revenues recognized in fiscal year 2013.
Cost of Revenues (in thousands):
|
|
|
|
Three Months Ended December 31,
|
|
|
|
|
Year Ended December 31,
|
|
|
|
|
2014
|
|
|
2013
|
|
|
|
|
|
2014
|
|
|
|
|
2013
|
Inventor royalties
|
|
|
|
$
|
4,358
|
|
|
$
|
3,280
|
|
|
|
|
|
$
|
20,670
|
|
|
|
|
$
|
29,724
|
Contingent legal fees
|
|
|
|
7,296
|
|
|
3,181
|
|
|
|
|
|
23,563
|
|
|
|
|
24,784
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fourth quarter 2014 revenues, less inventor royalties expense and
contingent legal fees expense totaled $19,376,000, or 62% of related
quarterly revenues, as compared to $8,604,000, or 57% of quarterly
revenues, in the comparable prior year quarter.
Fiscal year 2014 revenues, less inventor royalties expense and
contingent legal fees expense totaled $86,643,000, or 66% of related
fiscal year 2014 revenues, as compared to $76,048,000, or 58% of related
fiscal year 2013 revenues.
The increase in fourth quarter and fiscal year 2014 revenues, less
related inventor royalties and contingent legal fees expense, as a
percentage of related quarterly and annual revenues, respectively, was
primarily due to, on average, a higher percentage of revenues generated
in the fourth quarter and fiscal year 2014 having no inventor royalty
obligations, and lower overall inventor royalty rates, primarily due to
preferential returns on advances and cost recoveries, for the portfolios
generating revenues during the 2014 periods, as compared to the revenues
generated in the 2013 periods. Inventor royalties and contingent legal
fees expenses fluctuate period to period, based on the amount of
revenues recognized each period and the economic terms of the patent
portfolio partnering arrangements and contingent legal fee arrangements,
if any, associated with the specific patent portfolios generating
revenues each period.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended December 31,
|
|
|
|
Year Ended December 31,
|
|
|
|
|
|
2014
|
|
|
|
|
|
2013
|
|
|
|
|
2014
|
|
|
|
|
|
|
2013
|
Litigation and licensing expenses - patents
|
|
|
|
|
$
|
8,208
|
|
|
|
|
|
$
|
8,899
|
|
|
|
|
$
|
37,614
|
|
|
|
|
|
|
$
|
39,335
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fourth quarter 2014 and 2013 litigation and licensing expenses-patents
were relatively flat quarter to quarter. Fiscal year 2014 litigation and
licensing expenses-patents decreased due primarily to a net decrease in
litigation support and third-party technical consulting expenses
associated with ongoing and new licensing and enforcement programs
commenced during fiscal year 2014. We expect litigation and licensing
expenses to continue to fluctuate period to period in connection with
our current and future patent partnering, prosecution, licensing and
enforcement activities.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended December 31,
|
|
|
|
|
Year Ended December 31,
|
|
|
|
|
2014
|
|
|
|
|
2013
|
|
|
|
|
|
2014
|
|
|
|
|
2013
|
Amortization of patents
|
|
|
|
$
|
13,727
|
|
|
|
|
$
|
16,735
|
|
|
|
|
|
$
|
57,242
|
|
|
|
|
$
|
53,658
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The change in patent amortization expense for the periods presented was
due to the following:
|
|
|
|
|
Three Months Ended December 31,
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
|
|
2014 vs. 2013
|
|
|
|
|
|
2014 vs. 2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Patent portfolio investments since the end of the prior year period
|
|
|
|
|
$
|
920
|
|
|
|
|
|
|
$
|
2,534
|
|
Scheduled amortization related to patent portfolios acquired during
the prior year
|
|
|
|
|
(301
|
)
|
|
|
|
|
|
562
|
|
Accelerated amortization related to recovery of upfront advances
|
|
|
|
|
60
|
|
|
|
|
|
|
655
|
|
Patent portfolio dispositions
|
|
|
|
|
-
|
|
|
|
|
|
|
955
|
|
Patent portfolio impairment charges
|
|
|
|
|
(3,687
|
)
|
|
|
|
|
|
(1,122
|
)
|
Total change in patent amortization expense
|
|
|
|
|
$
|
(3,008
|
)
|
|
|
|
|
|
$
|
3,584
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Operating Expenses (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended December 31,
|
|
|
|
Year Ended December 31,
|
|
|
|
|
2014
|
|
|
|
|
2013
|
|
|
|
|
2014
|
|
|
|
|
2013
|
Marketing, general and administrative expenses
|
|
|
|
$
|
7,951
|
|
|
|
|
$
|
6,906
|
|
|
|
|
$
|
30,439
|
|
|
|
|
$
|
31,335
|
Non-cash stock compensation expense - MG&A
|
|
|
|
4,093
|
|
|
|
|
7,082
|
|
|
|
|
18,115
|
|
|
|
|
27,894
|
Total marketing, general and administrative expenses
|
|
|
|
$
|
12,044
|
|
|
|
|
$
|
13,988
|
|
|
|
|
$
|
48,554
|
|
|
|
|
$
|
59,229
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fourth quarter 2014 marketing, general and administrative expenses,
excluding non-cash stock compensation expense, increased $1,045,000 or
15%, due primarily to an increase in variable performance-based
compensation costs, consistent with the increase in revenues quarter to
quarter, and an increase in non-recurring employee severance and
corporate administrative costs. The increase was partially offset by an
overall decrease in personnel costs resulting from net staff reductions
occurring during the year.
Fiscal year 2014 marketing, general and administrative expenses,
excluding non-cash stock compensation expense, decreased $896,000 or 3%,
due primarily to a net decrease in personnel costs resulting from net
staff reductions occurring during fiscal 2014.
Fourth quarter and fiscal year 2014 non-cash stock compensation expense
decreased due to a decrease in the average grant date fair value for the
shares expensed in the respective periods, and a decrease in the number
of shares expensed during the periods resulting from a net reduction in
employee headcount and a decrease in the number of shares vesting for
current employees. Fiscal year 2013 non-cash stock compensation expense
included CEO retirement package related non-recurring non-cash charges
totaling $1,823,000.
Other Operating Expenses:
Fiscal year 2014 operating expenses included an expense accrual for
court ordered attorney fees related to separate matters initiated in
2010 and 2011 totaling $1,548,000. The respective operating subsidiaries
have filed notices of appeal. Fiscal year 2013 operating expenses
included a one-time, non-recurring charge related to the resolution of a
dispute concerning legal fees associated with a prior matter totaling
$3,506,000.
Income Taxes:
|
|
|
|
|
Three Months Ended December 31,
|
|
|
|
Year Ended December 31,
|
|
|
|
|
|
2014
|
|
|
|
|
2013
|
|
|
|
|
2014
|
|
|
|
|
2013
|
|
(Provision for) benefit from income taxes (in thousands)
|
|
|
|
|
$
|
(450
|
)
|
|
|
|
$
|
(3,390
|
)
|
|
|
|
$
|
(3,912
|
)
|
|
|
|
$
|
21,958
|
|
Effective tax rate
|
|
|
|
|
3
|
%
|
|
|
|
11
|
%
|
|
|
|
6
|
%
|
|
|
|
(27
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tax expense for the fourth quarter and fiscal year 2014 reflects the
impact of a full valuation allowance recorded for net operating loss and
foreign tax credit related tax assets generated during the periods. As
such, no tax benefit was recognized for net operating loss and foreign
tax credit related tax benefits generated during the 2014 periods. Tax
expense for the fourth quarter and fiscal year 2014 primarily reflects
foreign taxes withheld on revenue agreements with licensees in foreign
jurisdictions and other state taxes.
The tax benefit recognized for fiscal 2013 reflects the application of
an annual effective tax rate to the GAAP pre-tax net loss reported for
fiscal 2013. The fiscal year 2013 effective tax rate was lower than the
U.S. federal statutory rate primarily due to a partial increase in the
valuation allowance related to certain foreign tax credits generated in
2013 and certain nondeductible expenses.
Financial Condition (in thousands)
Summary Balance Sheet Information:
|
|
|
|
|
December 31, 2014
|
|
|
|
|
December 31, 2013
|
Cash and cash equivalents and investments
|
|
|
|
|
$
|
193,024
|
|
|
|
|
|
$
|
256,702
|
Accounts receivable
|
|
|
|
|
20,168
|
|
|
|
|
|
6,341
|
Total assets
|
|
|
|
|
536,348
|
|
|
|
|
|
593,393
|
Accounts payable and accrued expenses
|
|
|
|
|
14,860
|
|
|
|
|
|
11,555
|
Accrued patent portfolio investment costs
|
|
|
|
|
16,700
|
|
|
|
|
|
4,000
|
Royalties and contingent legal fees payable
|
|
|
|
|
14,351
|
|
|
|
|
|
10,447
|
Total liabilities
|
|
|
|
|
47,300
|
|
|
|
|
|
31,195
|
|
|
|
|
|
|
|
|
|
|
|
|
Summary Cash Flow Information:
|
|
|
|
|
Three Months Ended December 31,
|
|
|
|
|
Year Ended December 31,
|
|
|
|
|
|
2014
|
|
|
|
|
|
2013
|
|
|
|
|
|
2014
|
|
|
|
|
2013
|
|
Net cash provided by (used in):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating activities
|
|
|
|
|
$
|
(9,706
|
)
|
|
|
|
|
$
|
1,310
|
|
|
|
|
|
$
|
4,184
|
|
|
|
|
$
|
(3,509
|
)
|
Investing activities
|
|
|
|
|
(3,827
|
)
|
|
|
|
|
22,076
|
|
|
|
|
|
29,297
|
|
|
|
|
(66,059
|
)
|
Financing activities
|
|
|
|
|
(6,258
|
)
|
|
|
|
|
(15,004
|
)
|
|
|
|
|
(25,700
|
)
|
|
|
|
(25,551
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Patent Portfolio Investment Costs. Patent related upfront
advances and scheduled milestone payments paid in the fourth quarter of
2014 totaled $18,228,000, as compared to $14,645,000 during the
comparable prior year quarter.
Patent related upfront advances and scheduled milestone payments paid in
fiscal year 2014 totaled $42,746,000, as compared to $25,061,000 in
fiscal year 2013. Accrued patent portfolio investment costs totaled
$16,700,000 at December 31, 2014.
Quarterly Dividends Paid. Cash outflows from financing activities
included cash dividends to shareholders totaling $6,266,000 and
$25,039,000 for the fourth quarter and fiscal year ended December 31,
2014, respectively. Refer to our website for IRS Form 8937 information
related to the distribution announced herein and any previous
distributions.
See "Business Highlights and Recent Developments" below for a summary of
patent portfolio investments during the current quarter.
Refer to the section below entitled "Summary Financial Information" for
additional summary consolidated balance sheet, statements of operations
and cash flow information as of and for the applicable periods presented.
INFORMATION ABOUT NON-GAAP FINANCIAL MEASURES
As used herein, "GAAP" refers to accounting principles generally
accepted in the United States of America. To supplement our consolidated
financial statements prepared and presented in accordance with GAAP,
this earnings release includes financial measures, including (1)
non-GAAP net income and (2) non-GAAP Earnings Per Share ("EPS"), that
are considered non-GAAP financial measures as defined in Rule 101 of
Regulation G promulgated by the Securities and Exchange Commission.
Generally, a non-GAAP financial measure is a numerical measure of a
company's historical or future performance, financial position, or cash
flows that either excludes or includes amounts that are not normally
excluded or included in the most directly comparable measure calculated
and presented in accordance with GAAP. The presentation of this non-GAAP
financial information is not intended to be considered in isolation or
as a substitute for, or superior to, the financial information prepared
and presented in accordance with GAAP.
We use these non-GAAP, or pro forma, financial measures for internal
financial and operational decision making purposes and as a means to
evaluate period-to-period comparisons of the performance and results of
operations of our core business. Our management believes that these
non-GAAP financial measures provide meaningful supplemental information
regarding the performance of our core business by excluding non-cash
stock compensation charges, non-cash patent amortization charges, excess
benefit related non-cash tax expense and certain non-cash tax benefits,
that may not be indicative of our recurring core business operating
results. These non-GAAP financial measures also facilitate management's
internal planning and comparisons to our historical performance and
liquidity. We believe these non-GAAP financial measures are useful to
investors as they allow for greater transparency with respect to key
metrics used by management in its financial and operational decision
making and are used by our institutional investors and the analyst
community to help them analyze the performance and operational results
of our core business.
Non-GAAP Net income and EPS. We define non-GAAP net income as net
income calculated in accordance with GAAP, plus non-cash stock
compensation charges, non-cash patent amortization charges and excess
benefit related non-cash tax expense, less certain non-cash tax benefits
included in tax expense. Non-GAAP EPS is defined as non-GAAP net income
divided by the weighted average outstanding shares, on a fully-diluted
basis, calculated in accordance with GAAP, for the respective reporting
period.
Due to the inherent volatility in stock prices, the use of estimates and
assumptions in connection with the valuation and expensing of
share-based awards and the variety of award types that companies can
issue under FASB ASC Topic 718, management believes that providing a
non-GAAP financial measure that excludes non-cash stock compensation
allows investors to make meaningful comparisons between our recurring
core business operating results and those of other companies period to
period, as well as providing our management with a critical tool for
financial and operational decision making and for evaluating our own
period-to-period recurring core business operating results. Similarly,
due to the variability associated with the timing and amount of patent
portfolio investment payments and estimates inherent in the
capitalization and amortization of patent costs, management believes
that providing a non-GAAP financial measure that excludes non-cash
patent amortization charges allows investors to make meaningful
comparisons between our recurring core business operating results and
those of other companies, and also provides our management with a useful
tool for financial and operational decision making and for evaluating
our own period-to-period recurring core business operating results.
Management also believes that providing a non-GAAP financial measure
that excludes the impact of excess benefit related non-cash tax expense
and certain non-cash tax benefits included in tax expense allows
investors to assess our net results and the economic impact of income
taxes based largely on cash tax obligations, make more meaningful
comparisons between our recurring core business net results and those of
other companies period to period, and also provides our management with
a useful tool for financial and operational decision making and for
evaluating our own period-to-period recurring core business net results.
There are a number of limitations related to the use of non-GAAP net
income and EPS versus net income and EPS calculated in accordance with
GAAP. For example, non-GAAP net income excludes the impact of
significant non-cash stock compensation charges, non-cash patent
amortization charges, excess benefit related non-cash tax expense and
certain non-cash tax benefits included in tax expense that are or may be
recurring, and that may or will continue to be recurring for the
foreseeable future. In addition, non-cash stock compensation is a
critical component of our employee compensation programs and non-cash
patent amortization reflects the cost of certain patent portfolio
investments, amortized on a straight-line basis over the estimated
economic useful life of the respective patent portfolio, and may reflect
the acceleration of amortization related to recoupable up-front patent
portfolio costs. Management compensates for these limitations by
providing specific information regarding the GAAP amounts excluded from
non-GAAP net income and EPS and evaluating non-GAAP net income and EPS
in conjunction with net income and EPS calculated in accordance with
GAAP.
The accompanying table below provides a reconciliation of the non-GAAP
financial measures presented to the most directly comparable financial
measures prepared in accordance with GAAP.
_____________________________________________
A conference call is scheduled for today. The Acacia Research
presentation and Q&A will start at 1:30 p.m. Pacific Time (4:30 p.m.
Eastern).
To listen to the presentation by phone, dial (888) 299-7205 for domestic
callers and (719) 325-2301 for international callers, both of whom will
need to enter the conference ID 7520198 when prompted. A replay of the
audio presentation will be available for 30 days at (888) 203-1112 for
domestic callers and (719) 457-0820 for international callers, both of
whom will need to enter the Conference ID 7520198 when prompted.
The call is being webcast by CCBN and can be accessed at Acacia's
website at www.acaciaresearch.com.
ABOUT ACACIA RESEARCH CORPORATION
Founded in 1993, Acacia Research Corporation (NASDAQ: ACTG) is the
industry leader in patent licensing. An intermediary in the patent
marketplace, Acacia partners with inventors and patent owners to unlock
the financial value in their patented inventions. Acacia bridges the gap
between invention and application, facilitating efficiency and
delivering monetary rewards to the patent owner.
Information about Acacia Research Corporation and its subsidiaries is
available at www.acaciaresearch.com.
Safe Harbor Statement under the Private Securities Litigation Reform
Act of 1995
This news release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon
our current expectations and speak only as of the date hereof. Our
actual results may differ materially and adversely from those expressed
in any forward-looking statements as a result of various factors and
uncertainties, including the effect of the global economic downturn on
technology companies, the ability to successfully develop
licensing programs and attract new business, rapid technological change
in relevant markets, changes in demand for current and future
intellectual property rights, legislative, regulatory and competitive
developments addressing licensing and enforcement of patents and/or
intellectual property in general and general economic conditions.
Our Annual Report on Form 10-K, recent and forthcoming Quarterly
Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and
other SEC filings discuss some of the important risk factors that may
affect our business, results of operations and financial condition. We
undertake no obligation to revise or update publicly any forward-looking
statements for any reason.
The results achieved in the most recent quarter are not necessarily
indicative of the results to be achieved by us in any subsequent
quarters, as it is currently anticipated that Acacia Research
Corporation's financial results will vary, and may vary significantly,
from quarter to quarter. This variance is expected to result from
a number of factors, including risk factors affecting our results of
operations and financial condition referenced above, and the particular
structure of our licensing transactions, which may impact the amount of
inventor royalties and contingent legal fees expenses we incur period to
period.
|
ACACIA RESEARCH CORPORATION
|
SUMMARY FINANCIAL INFORMATION
|
(In thousands, except share and per share information)
|
(Unaudited)
|
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
|
|
|
|
|
|
|
Three Months Ended December 31,
|
|
|
|
|
Year Ended December 31,
|
|
|
|
|
|
2014
|
|
|
|
|
2013
|
|
|
|
|
|
2014
|
|
|
|
|
2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
|
|
|
|
|
$
|
31,030
|
|
|
|
|
$
|
15,065
|
|
|
|
|
|
$
|
130,876
|
|
|
|
|
$
|
130,556
|
|
Operating costs and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Inventor royalties
|
|
|
|
|
4,358
|
|
|
|
|
3,280
|
|
|
|
|
|
20,670
|
|
|
|
|
29,724
|
|
Contingent legal fees
|
|
|
|
|
7,296
|
|
|
|
|
3,181
|
|
|
|
|
|
23,563
|
|
|
|
|
24,784
|
|
Litigation and licensing expenses - patents
|
|
|
|
|
8,208
|
|
|
|
|
8,899
|
|
|
|
|
|
37,614
|
|
|
|
|
39,335
|
|
Amortization of patents
|
|
|
|
|
13,727
|
|
|
|
|
16,735
|
|
|
|
|
|
57,242
|
|
|
|
|
53,658
|
|
Marketing, general and administrative expenses (including non-cash
stock compensation expense of $4,093 and $18,115 for the three
months and year ended December 31, 2014, respectively, and $7,082
and $27,894 for the three months and year ended December 31, 2013,
respectively)
|
|
|
|
|
12,044
|
|
|
|
|
13,988
|
|
|
|
|
|
48,554
|
|
|
|
|
59,229
|
|
Research, consulting and other expenses - business development
|
|
|
|
|
637
|
|
|
|
|
742
|
|
|
|
|
|
3,840
|
|
|
|
|
3,251
|
|
Other
|
|
|
|
|
-
|
|
|
|
|
-
|
|
|
|
|
|
1,548
|
|
|
|
|
3,506
|
|
Total operating costs and expenses
|
|
|
|
|
46,270
|
|
|
|
|
46,825
|
|
|
|
|
|
193,031
|
|
|
|
|
213,487
|
|
Operating loss
|
|
|
|
|
(15,240
|
)
|
|
|
|
(31,760
|
)
|
|
|
|
|
(62,155
|
)
|
|
|
|
(82,931
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other income (expense)
|
|
|
|
|
(451
|
)
|
|
|
|
161
|
|
|
|
|
|
(595
|
)
|
|
|
|
2,131
|
|
Loss from operations before (provision for) benefit from income taxes
|
|
|
|
|
(15,691
|
)
|
|
|
|
(31,599
|
)
|
|
|
|
|
(62,750
|
)
|
|
|
|
(80,800
|
)
|
(Provision for) benefit from income taxes
|
|
|
|
|
(450
|
)
|
|
|
|
(3,390
|
)
|
|
|
|
|
(3,912
|
)
|
|
|
|
21,958
|
|
Net loss including noncontrolling interests in operating subsidiaries
|
|
|
|
|
(16,141
|
)
|
|
|
|
(34,989
|
)
|
|
|
|
|
(66,662
|
)
|
|
|
|
(58,842
|
)
|
Net (income) loss attributable to noncontrolling interests in
operating subsidiaries
|
|
|
|
|
(103
|
)
|
|
|
|
1,656
|
|
|
|
|
|
633
|
|
|
|
|
2,408
|
|
Net loss attributable to Acacia Research Corporation
|
|
|
|
|
$
|
(16,244
|
)
|
|
|
|
$
|
(33,333
|
)
|
|
|
|
|
$
|
(66,029
|
)
|
|
|
|
$
|
(56,434
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable to common stockholders - diluted
|
|
|
|
|
$
|
(16,399
|
)
|
|
|
|
$
|
(33,517
|
)
|
|
|
|
|
$
|
(66,755
|
)
|
|
|
|
$
|
(56,945
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted loss per common share
|
|
|
|
|
$
|
(0.34
|
)
|
|
|
|
$
|
(0.69
|
)
|
|
|
|
|
$
|
(1.37
|
)
|
|
|
|
$
|
(1.18
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of shares outstanding, diluted
|
|
|
|
|
48,944,914
|
|
|
|
|
48,415,684
|
|
|
|
|
|
48,658,088
|
|
|
|
|
48,155,832
|
|
|
Reconciliation of GAAP Net Loss and EPS to Non-GAAP Net Income
(Loss) and EPS
|
(In thousands, except share and per share data)
|
|
|
|
|
|
|
|
Three Months Ended December 31,
|
|
|
|
|
Year Ended December 31,
|
|
|
|
|
|
2014
|
|
|
|
|
|
2013
|
|
|
|
|
|
2014
|
|
|
|
|
|
2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP net loss
|
|
|
|
|
$
|
(16,244
|
)
|
|
|
|
|
$
|
(33,333
|
)
|
|
|
|
|
$
|
(66,029
|
)
|
|
|
|
|
$
|
(56,434
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-cash stock compensation
|
|
|
|
|
4,093
|
|
|
|
|
|
7,082
|
|
|
|
|
|
18,115
|
|
|
|
|
|
27,894
|
|
Non-cash patent amortization
|
|
|
|
|
13,727
|
|
|
|
|
|
16,735
|
|
|
|
|
|
57,242
|
|
|
|
|
|
53,658
|
|
Non-cash tax benefits
|
|
|
|
|
-
|
|
|
|
|
|
(1,040
|
)
|
|
|
|
|
-
|
|
|
|
|
|
(26,542
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pro forma non-GAAP net income (loss)
|
|
|
|
|
$
|
1,576
|
|
|
|
|
|
$
|
(10,556
|
)
|
|
|
|
|
$
|
9,328
|
|
|
|
|
|
$
|
(1,424
|
)
|
Pro forma non-GAAP net income (loss) attributable to common
stockholders - diluted
|
|
|
|
|
$
|
1,530
|
|
|
|
|
|
$
|
(10,740
|
)
|
|
|
|
|
$
|
9,020
|
|
|
|
|
|
$
|
(1,935
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pro forma non-GAAP net earnings (loss) per common share - diluted
|
|
|
|
|
$
|
0.03
|
|
|
|
|
|
$
|
(0.22
|
)
|
|
|
|
|
$
|
0.18
|
|
|
|
|
|
$
|
(0.04
|
)
|
GAAP weighted-average shares - diluted
|
|
|
|
|
49,079,030
|
|
|
|
|
|
48,415,684
|
|
|
|
|
|
48,785,441
|
|
|
|
|
|
48,155,832
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ACACIA RESEARCH CORPORATION
|
SUMMARY FINANCIAL INFORMATION, (CONTINUED)
|
(In thousands)
|
(Unaudited)
|
|
CONDENSED CONSOLIDATED BALANCE SHEET INFORMATION
|
|
|
|
|
|
|
December 31, 2014
|
|
|
|
|
December 31, 2013
|
ASSETS
|
|
|
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
|
|
|
$
|
134,466
|
|
|
|
|
|
$
|
126,685
|
Short-term investments
|
|
|
|
|
58,558
|
|
|
|
|
|
130,017
|
Accounts receivable
|
|
|
|
|
20,168
|
|
|
|
|
|
6,341
|
Deferred income tax
|
|
|
|
|
1,161
|
|
|
|
|
|
3,139
|
Prepaid expenses and other current assets
|
|
|
|
|
4,355
|
|
|
|
|
|
7,546
|
Total current assets
|
|
|
|
|
218,708
|
|
|
|
|
|
273,728
|
|
|
|
|
|
|
|
|
|
|
|
|
Property and equipment, net of accumulated depreciation and
amortization
|
|
|
|
|
500
|
|
|
|
|
|
766
|
Patents, net of accumulated amortization
|
|
|
|
|
286,636
|
|
|
|
|
|
288,432
|
Goodwill
|
|
|
|
|
30,149
|
|
|
|
|
|
30,149
|
Other assets
|
|
|
|
|
355
|
|
|
|
|
|
318
|
|
|
|
|
|
$
|
536,348
|
|
|
|
|
|
$
|
593,393
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
Accounts payable and accrued expenses
|
|
|
|
|
$
|
14,860
|
|
|
|
|
|
$
|
11,555
|
Accrued patent investment costs
|
|
|
|
|
16,700
|
|
|
|
|
|
4,000
|
Royalties and contingent legal fees payable
|
|
|
|
|
14,351
|
|
|
|
|
|
10,447
|
Total current liabilities
|
|
|
|
|
45,911
|
|
|
|
|
|
26,002
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred income taxes
|
|
|
|
|
1,161
|
|
|
|
|
|
4,874
|
Other liabilities
|
|
|
|
|
228
|
|
|
|
|
|
319
|
Total liabilities
|
|
|
|
|
47,300
|
|
|
|
|
|
31,195
|
Total stockholders' equity
|
|
|
|
|
489,048
|
|
|
|
|
|
562,198
|
|
|
|
|
|
$
|
536,348
|
|
|
|
|
|
$
|
593,393
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ACACIA RESEARCH CORPORATION
|
SUMMARY FINANCIAL INFORMATION, (CONTINUED)
|
(In thousands)
|
(Unaudited)
|
|
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
|
|
|
|
|
|
Three Months Ended December 31,
|
|
|
|
|
Year Ended December 31,
|
|
|
|
|
|
2014
|
|
|
|
|
2013
|
|
|
|
|
|
2014
|
|
|
|
|
2013
|
|
Cash flows from operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss including noncontrolling interests in operating subsidiaries
|
|
|
|
|
$
|
(16,141
|
)
|
|
|
|
$
|
(34,989
|
)
|
|
|
|
|
$
|
(66,662
|
)
|
|
|
|
$
|
(58,842
|
)
|
Adjustments to reconcile net loss including noncontrolling interests
in operating subsidiaries to net cash provided by (used in)
operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
|
|
13,793
|
|
|
|
|
16,809
|
|
|
|
|
|
57,546
|
|
|
|
|
53,894
|
|
Non-cash stock compensation
|
|
|
|
|
4,093
|
|
|
|
|
7,082
|
|
|
|
|
|
18,115
|
|
|
|
|
27,894
|
|
Excess tax benefits from stock-based compensation
|
|
|
|
|
-
|
|
|
|
|
1,040
|
|
|
|
|
|
-
|
|
|
|
|
1,398
|
|
Change in valuation allowance on net deferred tax assets
|
|
|
|
|
-
|
|
|
|
|
2,189
|
|
|
|
|
|
-
|
|
|
|
|
2,189
|
|
Other
|
|
|
|
|
(4
|
)
|
|
|
|
34
|
|
|
|
|
|
(28
|
)
|
|
|
|
12
|
|
Changes in assets and liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
|
|
(7,466
|
)
|
|
|
|
10,471
|
|
|
|
|
|
(13,827
|
)
|
|
|
|
3,502
|
|
Prepaid expenses and other assets
|
|
|
|
|
1,435
|
|
|
|
|
566
|
|
|
|
|
|
3,154
|
|
|
|
|
(5,300
|
)
|
Accounts payable and accrued expenses
|
|
|
|
|
(1,786
|
)
|
|
|
|
(5,798
|
)
|
|
|
|
|
3,717
|
|
|
|
|
1,076
|
|
Royalties and contingent legal fees payable
|
|
|
|
|
(3,426
|
)
|
|
|
|
2,134
|
|
|
|
|
|
3,904
|
|
|
|
|
(2,061
|
)
|
Deferred taxes, net
|
|
|
|
|
(204
|
)
|
|
|
|
1,772
|
|
|
|
|
|
(1,735
|
)
|
|
|
|
(27,271
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) operating activities
|
|
|
|
|
(9,706
|
)
|
|
|
|
1,310
|
|
|
|
|
|
4,184
|
|
|
|
|
(3,509
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from investing activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchases of property and equipment
|
|
|
|
|
(3
|
)
|
|
|
|
(96
|
)
|
|
|
|
|
(109
|
)
|
|
|
|
(675
|
)
|
Purchase of available-for-sale investments
|
|
|
|
|
(33,833
|
)
|
|
|
|
(46,884
|
)
|
|
|
|
|
(109,963
|
)
|
|
|
|
(279,693
|
)
|
Maturities and sales of available-for-sale investments
|
|
|
|
|
48,237
|
|
|
|
|
83,701
|
|
|
|
|
|
182,115
|
|
|
|
|
239,370
|
|
Investments in patents / patent rights
|
|
|
|
|
(18,228
|
)
|
|
|
|
(14,645
|
)
|
|
|
|
|
(42,746
|
)
|
|
|
|
(25,061
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) investing activities
|
|
|
|
|
(3,827
|
)
|
|
|
|
22,076
|
|
|
|
|
|
29,297
|
|
|
|
|
(66,059
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Repurchases of common stock
|
|
|
|
|
-
|
|
|
|
|
(7,908
|
)
|
|
|
|
|
-
|
|
|
|
|
(7,926
|
)
|
Dividends paid to shareholders
|
|
|
|
|
(6,266
|
)
|
|
|
|
(6,241
|
)
|
|
|
|
|
(25,039
|
)
|
|
|
|
(18,633
|
)
|
Distributions to noncontrolling interests in operating subsidiary
|
|
|
|
|
-
|
|
|
|
|
-
|
|
|
|
|
|
(867
|
)
|
|
|
|
-
|
|
Contributions from noncontrolling interests in operating subsidiary
|
|
|
|
|
-
|
|
|
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
1,920
|
|
Excess tax benefits from stock-based compensation
|
|
|
|
|
-
|
|
|
|
|
(1,040
|
)
|
|
|
|
|
-
|
|
|
|
|
(1,398
|
)
|
Proceeds from exercises of stock options
|
|
|
|
|
8
|
|
|
|
|
185
|
|
|
|
|
|
206
|
|
|
|
|
486
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in financing activities
|
|
|
|
|
(6,258
|
)
|
|
|
|
(15,004
|
)
|
|
|
|
|
(25,700
|
)
|
|
|
|
(25,551
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Increase (decrease) in cash and cash equivalents
|
|
|
|
|
(19,791
|
)
|
|
|
|
8,382
|
|
|
|
|
|
7,781
|
|
|
|
|
(95,119
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents, beginning
|
|
|
|
|
154,257
|
|
|
|
|
118,303
|
|
|
|
|
|
126,685
|
|
|
|
|
221,804
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents, ending
|
|
|
|
|
$
|
134,466
|
|
|
|
|
$
|
126,685
|
|
|
|
|
|
$
|
134,466
|
|
|
|
|
$
|
126,685
|
|
Business Highlights and Recent Developments(2)
Business highlights of the fourth quarter of 2014 and recent
developments include the following:
Revenues for the three months ended December 31, 2014 included fees from
the following technology licensing and enforcement programs:
•
|
3G & 4G Cellular Air Interface and Infrastructure technology
|
|
|
|
•
|
Mobile Computer Synchronization technology
|
•
|
4G Wireless technology
|
|
|
|
•
|
Oil and Gas Production technology(1)
|
•
|
Audio Communications Fraud Detection technology
|
|
|
|
•
|
Online Auction Guarantee technology
|
•
|
Automotive Safety, Navigation and Diagnostics technology
|
|
|
|
•
|
Online newsletters with links technology
|
•
|
Broadband Communications technology
|
|
|
|
•
|
Optical Networking technology
|
•
|
Cardiology and Vascular Device technology(1)
|
|
|
|
•
|
Optimized Microprocessor Operation technology(1)
|
•
|
Distributed Data Management & Synchronization technology(1)
|
|
|
|
•
|
Reflective and Radiant Barrier Insulation technology
|
•
|
Enhanced Mobile Communications technology
|
|
|
|
•
|
Super Resolutions Microscopy technology
|
•
|
Gas Modulation Control Systems technology
|
|
|
|
•
|
Suture Anchors technology
|
•
|
High Speed Circuit Interconnect and Display Control technology(1)
|
|
|
|
•
|
Telematics technology
|
•
|
Innovative Display technology
|
|
|
|
•
|
Voice-Over-IP technology
|
•
|
Intercarrier SMS technology
|
|
|
|
•
|
Wireless Infrastructure and User Equipment technology
|
•
|
Interstitial and Pop-Up Internet Advertising technology
|
|
|
|
•
|
Wireless Monitoring technology
|
•
|
Messaging technology
|
|
|
|
|
|
_______________________
(*) Initial license fees were recorded for these
licensing programs in the fourth quarter of 2014.
-
Acacia Research Corporation resolved the dispute initiated by
Microsoft Corporation in the United States District Court for the
Southern District of New York, Civil Action No. 1:13-cv-08275.
The
following actions brought by Acacia subsidiaries were also resolved as
they relate to Microsoft: Intercarrier Communications LLC v. Microsoft
Corp., et al., Case No. 1:13-cv-01639-GMS (D. Del.); Optimum Content
Protection LLC v. Microsoft Corp., Case No. 6:13-cv-00741-KNM (E.D.
Tex.); Internet Communications Solutions LLC v. Microsoft Corp., Skype
Inc, and Skype Communications SARL, Case No. 2:14-cv-00189-JRG (E.D.
Tex.); Cell and Network Selection LLC v. BlackBerry Corp. et al, Case
No. 6:13-cv-00563-KNM (E.D. Tex.); Mobile Enhancement Solutions LLC v.
Microsoft Mobile Oy & Nokia Inc, Case No. 3:13-cv-03977-MGL (N.D.
Tex.); Super Interconnect Technologies v. Microsoft Mobile Oy & Nokia
Inc, Case No. 6:13-cv-00739-KNM (E.D. Tex.), Case No.
3:14-cv-2293-H-BGS (S.D. Cal.).
In addition, the action
entitled Cellular Communications Equipment LLC v. HTC Corp., et al.,
Case No. 6:13-cv-00738-LED/ 6:13-cv-00507-LED (E.D. Tex.) was
dismissed with respect to Microsoft without prejudice.
-
ADAPTIX, Inc. entered into a settlement and patent license agreement
with Huawei Technologies Co., Ltd. for limited rights on user
equipment. The agreement resolved litigation that was pending in the
United States District Court for the Eastern District of Texas and
litigation that was pending in Tokyo District Court asserting patent
infringement by certain Huawei user equipment.
-
Adaptix, Inc. entered into a settlement and patent license agreement
with NEC Corporation and its subsidiaries for certain limited rights
to the Adaptix patent portfolio. This agreement resolved litigation
that was pending in the United States District Court for the Eastern
District of Texas.
-
Auto-Dimensions LLC and Dassault Systems SolidWorks Corporation
resolved the dispute between the parties that was pending in the
United States District Court for the District of Massachusetts, Civil
Action No. 1:13-cv-12747.
-
Body Science LLC entered into a settlement agreement with A&D
Engineering, Inc. regarding wireless medical diagnostic and monitoring
systems. The agreement resolved litigation that was pending in the
United States District Court for the District of Massachusetts.
-
Bonutti Skeletal Innovations LLC entered into a settlement and patent
license agreement with DePuy Mitek LLC. The agreement resolved
litigation that was pending in the United States District Court for
the District of Massachusetts.
-
Bonutti Skeletal Innovations LLC entered into a settlement and patent
license agreement with ConforMIS, Inc. The agreement resolved all
aspects of the litigation for the United States District Court for the
District of Delaware and the United States District Court for the
District of Massachusetts.
-
Brandywine Communications Technologies LLC entered into a
royalty-bearing patent license agreement with Gutierrez-Palmenberg,
Inc. dba Phoenix Internet.
-
Brandywine Communications Technologies LLC entered into a settlement
and patent license agreement with MegaPath Corporation. The agreement
resolved litigation that was pending in the United States District
Court for the District of Delaware.
-
Cell and Network Selection LLC and SOTA Semiconductor LLC entered into
an agreement with RPX Corporation.
-
Cell and Network Selection LLC entered into a limited rights patent
license agreement with NEC Corporation and its subsidiaries.
-
Cell and Network Selection LLC and AT&T Mobility LLC reached a
settlement that resolved the dispute between the parties currently
pending in the United States District Court for the Eastern District
of Texas, Civil Action No. 6:13-cv-00403.
-
Cellular Communications Equipment LLC entered into a settlement and
limited rights patent license agreement with NEC Corporation and its
subsidiaries. The agreement resolved litigation that was pending in
the United States District Court for the Eastern District of Texas.
-
Credit Card Fraud Control Corporation entered into a settlement and
patent license agreement with TCSP Inc. dba TrustCommerce. The
agreement resolved litigation that was pending in the United States
District Court for the Northern District of Texas.
-
Credit Card Fraud Control Corporation entered into a settlement and
license agreement with Chase Paymentech Solutions, LLC. The agreement
resolved patent litigation, Civil Action No. 3:14-cv-2671, pending in
the United States District Court for the Northern District of Texas,
Dallas Division.
-
Credit Card Fraud Control Corporation entered into a settlement and
license agreement with First Data Corporation. This agreement resolved
patent litigation, Civil Action No. 3:14-cv-2619, pending in the
United States District Court for the Northern District of Texas,
Dallas Division.
-
Database Sync Solutions LLC entered into a settlement and patent
license agreement with International Business Machines Corporation.
The agreement resolved litigation that was pending in the United
States District Court for the Eastern District of Texas.
-
Innovative Display Technologies LLC and Delaware Display Group LLC
entered into a settlement and patent license agreement with HTC
Corporation and HTC America, Inc. The agreement resolved litigation
that was pending in the United States District Court for the District
of Delaware.
-
Labyrinth Optical Technologies LLC, Ciena Communications, Inc. and
Ciena Corporation have reached a settlement that resolved the dispute
between the parties currently pending in the United States District
Court for the Central District of California, Civil Action No.
8:12-cv-02217.
-
LifeScreen Sciences LLC entered into a settlement and patent license
agreement with Cordis Corporation. The agreement resolved litigation
that was pending in the United States District Court for the Eastern
District of Texas.
-
Online News Link LLC entered into a settlement with Epsilon Data
Management, LLC. The agreement resolved litigation that was pending in
the United States District Court for the Northern District of Texas,
Dallas Division.
-
Parallel Separation Innovations LLC entered into a Settlement and
Release Agreement with Axiom Process, LLC and Axiom Process Ltd. The
agreement resolved litigation that was pending in the United States
District Court for the Eastern District of Texas.
-
Smartphone Technologies LLC, ASUSTeK Computer Inc., and ASUS Computer
International reached a settlement that resolved the dispute between
the parties currently pending in the United States District Court for
the Eastern District of Texas, Civil Action Nos. 6:13-cv-807 and
6:14-cv-803.
-
Super Resolution Technologies LLC and Carl Zeiss Microscopy, LLC and
Carl Zeiss Microscopy, GmbH reached a resolution of their dispute over
the Fluorescent Nanoscopy patents. The agreement resolved litigation
that was pending in the United States District Court for the Southern
District of Texas.
-
Unified Messaging Solutions LLC entered into a settlement and patent
license agreement with Huntington Bancshares, Inc. The agreement
resolved litigation that was pending in the United States District
Court for the Northern District of Illinois.
-
Unified Messaging Solutions LLC entered into a settlement and patent
license agreement with The Vanguard Group, Inc. and Vanguard Marketing
Corporation. The agreement resolved litigation that was pending in the
United States District Court for the Southern District of New York.
-
Acacia Research Group LLC and its affiliates continued their patent
and patent rights investment activities, investing in a total of 2 new
patent portfolios in the fourth quarter of 2014, including the
following:
-
In December 2014, sourced rights in additional patent portfolios
from Nokia Networks. With these new portfolios, Acacia's
subsidiary now controls marquee portfolios relating to 2G/3G/LTE
and LTE-Advanced technologies.
_______________________
(1) As used herein, "Acacia Research Corporation," "we,"
"us," and "our" refer to Acacia Research Corporation and/or its wholly
and majority-owned operating subsidiaries. All intellectual property
investment, development, licensing and enforcement activities are
conducted solely by certain of Acacia Research Corporation's wholly and
majority-owned operating subsidiaries.
(2) Acacia Research Group LLC, ADAPTIX, Inc., Auto-Dimensions
LLC, Body Science LLC, Bonutti Skeletal Innovations LLC, Brandywine
Communications Technologies LLC, Cell and Network Selection LLC,
Cellular Communications Equipment LLC, Credit Card Fraud Control
Corporation, Database Sync Solutions LLC, Delaware Display Group LLC,
Innovative Display Technologies LLC, Labyrinth Optical Technologies LLC,
LifeScreen Sciences LLC, Online News Link LLC, Parallel Separation
Innovations LLC, Smartphone Technologies LLC, SOTA Semiconductor LLC,
Super Resolution Technologies LLC and Unified Messaging Solutions LLC
are wholly and majority-owned operating subsidiaries of Acacia Research
Corporation.
[ Back To TMCnet.com's Homepage ]
|